David Cendon Garcia / eu-startups - Dark Blue Therapeutics, a British discovery and development BioTech company innovating the next generation of precision oncology medicines, has been acquired by US-based global BioTech company Amgen, in a transaction valued at up to €718 million ($840 mil…
Back to Top / Wednesday, January 7, 2026, 9:21 am / permalink 17591 / 5 stories in 1 month
Welsh biotech Antiverse raises $9.3M to advance AI-designed antibodies / 3 days
UK biotech Nuclera secures Series C funding for advanced protein research / 7 wks
Sweden’s Lithea secures funding for childhood cancer therapy / 4 months
Eli Lilly to acquire Orna Therapeutics in a $2.4B biotech deal / 25 days
Adaptam Therapeutics secures €3M for cancer immunotherapy research / 4 months
Novartis Acquires Avidity Biosciences for $12 Billion Expansion / 4 months
Dwelly raises over €79M to scale its AI-enabled UK rental marketplace / 9 days
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.